Cent Eur J Public Health 2022, 30(3):144-153 | DOI: 10.21101/cejph.a7079

Use of psychedelics in the Czech Republic: results of recent population surveys

Pavla Chomynová1, 2, 3, Rita Kočárová1, 4, 5, Filip Kňažek1, 6, Michaela Plevková1, Barbora Bláhová1, Karel Valeš1, Viktor Mravčík1, 3, 7
1 National Institute of Mental Health, Klecany, Czech Republic
2 Czech National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic
3 Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
4 Faculty of Arts, Charles University, Prague, Czech Republic
5 Beyond Psychedelics, Prague, Czech Republic
6 Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
7 Spolecnost Podane ruce, Brno, Czech Republic

Objectives: Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general population. The main aim of this study is to estimate the numbers of users of substances with psychedelic properties (classical psychedelics, cannabis, ecstasy, and ketamine) in the Czech Republic.

Methods: Data from two samples enrolled in representative cross-sectional questionnaire surveys in the Czech adult population in 2016 (n = 2,785) and 2018 (n = 1,665) were analysed. Prevalence rates were extrapolated to estimate numbers of current, i.e., last-year, users of psychedelics, and their socio-demographic profiles were compared with non-users and users of cannabis.

Results: An estimated 5-6% of the Czech adult population (350-430 thousand people) used classical psychedelics (LSD, psilocybin mushrooms, ayahuasca) in their lifetime, increasing up to 28-30% when cannabis is included (1.9-2.1 million users). Current use of classical psychedelics reached 0.7-1.9% (50-130 thousand people), and 9-11% (590-750 thousand users) when cannabis was included. Users of psychedelics were more often males, of younger age and single.

Conclusions: No significant socio-demographic differences were found between users of classical psychedelics and recreational cannabis users, however, differences were significant when compared to non-users and users of other illicit drugs. Findings should further serve to inform drug policy and social and healthcare systems in respect to the use of psychedelics.

Keywords: psychedelics, hallucinogens, cannabis, medical cannabis, substance use, epidemiology

Received: August 27, 2021; Revised: July 26, 2022; Accepted: July 26, 2022; Published: September 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chomynová P, Kočárová R, Kňažek F, Plevková M, Bláhová B, Valeš K, Mravčík V. Use of psychedelics in the Czech Republic: results of recent population surveys. Cent Eur J Public Health. 2022;30(3):144-153. doi: 10.21101/cejph.a7079. PubMed PMID: 36239361.
Download citation

References

  1. Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence. Time Mind. 2015;8(1):91-112. Go to original source...
  2. Schultes RE. Hallucinogens of plant origin. Science. 1969;163(3864):245-54. Go to original source... Go to PubMed...
  3. Hofmann A, Rätsch C. Plants of the gods: their sacred, healing, and hallucinogenic powers. Rochester, Vermont: Healing Arts Press; 2001.
  4. Akers BP, Ruiz JF, Piper A, Ruck CA. A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Economic Botany. 2011;65(2):121-8. Go to original source...
  5. Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proc Natl Acad Sci U S A. 2019;116(23):11207-12. Go to original source... Go to PubMed...
  6. Hazekamp A, Pappas G. Self-medication with cannabis. In: Pertwee RG, editor. Handbook of Cannabis. New York: Oxford University Press; 2014. p. 319-38. Go to original source...
  7. Mason NL, Kuypers KP. Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics. J Psychedelic Stud. 2018;2(1):45-52. Go to original source...
  8. Harris R, Gurel L. A study of ayahuasca use in North America. J Psychoactive Drugs. 2012;44(3):209-15. Go to original source... Go to PubMed...
  9. Kavenská V, Vosáhlová Š. Experience with ayahuasca in Europe - motives, possible benefits and risks. E-psychologie. 2013;4(7):28-39. (In Czech.)
  10. Móró L, Simon K, Bárd I, Rácz J. Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs. 2011;43(3):188-98. Go to original source... Go to PubMed...
  11. Bláhová B, Horák M, Verter N. Self-medication with cannabis in the Czech Republic from an anthropological perspective. Anthropologia Integra. 2017;8(2):77-87. Go to original source...
  12. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355. Go to original source... Go to PubMed...
  13. Gallimore AR. Restructuring consciousness - the psychedelic state in light of integrated information theory. Front Hum Neurosci. 2015;9:346. doi: 10.3389/fnhum.2015.00346. Go to original source... Go to PubMed...
  14. Freedman DX. The psychopharmacology of hallucinogenic agents. Annu Rev Med. 1969;20:409-18. Go to original source... Go to PubMed...
  15. Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32(7):811-9. Go to original source... Go to PubMed...
  16. Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166. Go to original source... Go to PubMed...
  17. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-61. Go to original source... Go to PubMed...
  18. Dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6(3):193-213. Go to original source... Go to PubMed...
  19. Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, von Heyden M, Aicher H, et al. Positive psychology in the investigation of psychedelics and entactogens: a critical review. Neuropharmacology. 2018;142:179-99. Go to original source... Go to PubMed...
  20. Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA) - assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109735. doi: 10.1016/j.pnpbp.2019.109735. Go to original source... Go to PubMed...
  21. Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209-19. Go to original source... Go to PubMed...
  22. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180-8.
  23. Carhart-Harris RL, Nutt D. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Substance Use. 2010;15(4):283-300. Go to original source...
  24. Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. doi: 10.1371/journal.pone.0063972. Go to original source... Go to PubMed...
  25. Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270-9. Go to original source... Go to PubMed...
  26. Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280-8. Go to original source... Go to PubMed...
  27. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558-65. Go to original source... Go to PubMed...
  28. Coomber R. Assessing the real dangers of illicit drugs - risk analysis as the way forward? Addict Res. 1999;7(2):85-90. Go to original source...
  29. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-20. Go to original source... Go to PubMed...
  30. European Monitoring Centre for Drugs and Drug Addiction. Handbook for surveys on drug use among the general population: EMCDDA project CT.99.EP.08 B. Lisbon: EMCDDA; 2002.
  31. Chomynová P, Mravčík V. National survey on substance use 2016. Zaostřeno. 2018;4(2):1-20. (In Czech.)
  32. Mravčík V, Chomynová P, Grohmannová K, Janíková B, Černíková T, Rous Z, et al. Annual report on drug situation in the Czech Republic in 2018. Prague: Government of the Czech Republic; 2019. (In Czech.)
  33. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: trends and developments. Luxembourg: Publications Office of the European Union; 2020.
  34. Mravčík V, Chomynová P, Grohmannová K, Janíková B, Černíková T, Rous Z, et al. Annual report on drug situation in the Czech Republic in 2019. Prague: Government of the Czech Republic; 2020. (In Czech.)
  35. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: trends and developments. Luxembourg: Publications Office of the European Union; 2019.
  36. Chomynová P, Csémy L, Mravčík V. European School Survey Project on Alcohol and Other Drugs (ESPAD) 2019. Zaostřeno. 2020;6(5):1-20. (In Czech.)
  37. ESPAD Group. ESPAD Report 2019: results from the European School Survey on Alcohol and Other Drugs. Luxembourg: Publications Office of the European Union; 2020.
  38. Zuckerman M, Neeb M. Demographic influences in sensation seeking and expressions of sensation seeking in religion, smoking and driving habits. Pers Individ Diff. 1980;1(3):197-206. Go to original source...
  39. Martin CA, Kelly TH, Rayens MK, Brogli BR, Brenzel A, Smith WJ, et al. Sensation seeking, puberty, and nicotine, alcohol, and marijuana use in adolescence. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1495-502. Go to original source... Go to PubMed...
  40. Donohew RL, Hoyle RH, Clayton RR, Skinner WF, Colon SE, Rice RE. Sensation seeking and drug use by adolescents and their friends: models for marijuana and alcohol. J Stud Alcohol. 1999;60(5):622-31. Go to original source... Go to PubMed...
  41. Crawford AM, Pentz MA, Chou C-P, Li C, Dwyer JH. Parallel developmental trajectories of sensation seeking and regular substance use in adolescents. Psychol Addict Behav. 2003;17(3):179-92. Go to original source... Go to PubMed...
  42. Hittner JB, Swickert R. Sensation seeking and alcohol use: a meta-analytic review. Addict Behav. 2006;31(8):1383-401. Go to original source... Go to PubMed...
  43. Zuckerman M. Sensation seeking and risky behavior. Washington, DC: American Psychological Association; 2007. Go to original source...
  44. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007;20(4):359-64. Go to original source... Go to PubMed...
  45. Thomsen PH. Schizophrenia with childhood and adolescent onset - a nationwide register-based study. Acta Psychiatr Scand. 1996;94(3):187-93. Go to original source... Go to PubMed...
  46. Vogels N, Brunt TM, Rigter S, Van Dijk P, Vervaeke H, Niesink RJM. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009;104(12):2057-66. Go to original source... Go to PubMed...
  47. Palamar JJ. There's something about Molly: the underresearched yet popular powder form of ecstasy in the United States. Subs Abus. 2017;38(1):15-7. Go to original source... Go to PubMed...
  48. van der Gouwe D, Brunt TM, van Laar M, van der Pol P. Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands. Addiction. 2017;112(4):640-8. Go to original source... Go to PubMed...